Schizophrenia genomics and proteomics: are we any closer to biomarker discovery?
2009

Schizophrenia Genomics and Proteomics: Progress Towards Biomarker Discovery

publication Evidence: moderate

Author Information

Author(s): Lakhan Shaheen E, Kramer Alon

Primary Institution: Global Neuroscience Initiative Foundation, Los Angeles, CA, USA

Hypothesis

Can biological markers be identified for schizophrenia through genomics and proteomics?

Conclusion

While significant progress has been made in schizophrenia biomarker research, no definitive biomarkers have been discovered yet.

Supporting Evidence

  • Over 2 million people in the US are affected by schizophrenia.
  • Recent studies show cerebrospinal fluid may hold potential biomarkers.
  • Genetic studies have identified candidate genes linked to schizophrenia.
  • International cooperation is enhancing research efforts in schizophrenia.

Takeaway

Scientists are trying to find special markers in the body that can help diagnose schizophrenia, but they haven't found any good ones yet.

Methodology

The review summarizes recent studies in genomics and proteomics related to schizophrenia biomarkers.

Limitations

The review highlights the need for larger studies and better standardization in biomarker research.

Digital Object Identifier (DOI)

10.1186/1744-9081-5-2

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication